Imlunestrant has 3 known drug interactions based on U.S. FDA drug labeling data. 3 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Cyp3a Inducers, Mao Inhibitors, P-Gp Or Bcrp Substrates. Patients taking Imlunestrant should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 3
- Major
- 3
Major (3)
- Imlunestrant + Cyp3a Inducers— Concomitant use decreases imlunestrant exposure, which may reduce effectiveness. Avoid concomitant use; if unavoidable, …
- Imlunestrant + Mao Inhibitors— Concomitant use increases imlunestrant exposure, which may increase the risk of adverse reactions. Avoid concomitant use…
- Imlunestrant + P-Gp Or Bcrp Substrates— Imlunestrant inhibits P-gp and BCRP, increasing substrate exposure and risk of adverse reactions. Avoid concomitant use …